Ocular Therapeutix (NASDAQ:OCUL) Insider Pravin Dugel Sells 21,156 Shares of Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Pravin Dugel sold 21,156 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $8.20, for a total transaction of $173,479.20. Following the sale, the insider owned 2,597,170 shares of the company’s stock, valued at approximately $21,296,794. The trade was a 0.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ocular Therapeutix Stock Up 7.1%

Ocular Therapeutix stock opened at $9.15 on Friday. The company has a 50-day simple moving average of $8.79 and a 200-day simple moving average of $10.23. The firm has a market capitalization of $2.00 billion, a P/E ratio of -6.27 and a beta of 0.93. The company has a debt-to-equity ratio of 0.12, a quick ratio of 14.73 and a current ratio of 14.81. Ocular Therapeutix, Inc. has a one year low of $6.23 and a one year high of $16.44.

Institutional Investors Weigh In On Ocular Therapeutix

A number of institutional investors and hedge funds have recently bought and sold shares of OCUL. Steward Partners Investment Advisory LLC lifted its holdings in Ocular Therapeutix by 124.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,242 shares during the last quarter. Rockefeller Capital Management L.P. purchased a new stake in Ocular Therapeutix during the fourth quarter valued at about $31,000. Hilton Head Capital Partners LLC lifted its stake in Ocular Therapeutix by 30.4% during the first quarter. Hilton Head Capital Partners LLC now owns 4,520 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 1,053 shares in the last quarter. Atlas Capital Advisors Inc. purchased a new stake in Ocular Therapeutix during the fourth quarter valued at about $61,000. Finally, KBC Group NV purchased a new stake in Ocular Therapeutix during the fourth quarter valued at about $78,000. 59.21% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. HC Wainwright restated a “buy” rating and set a $21.00 price target on shares of Ocular Therapeutix in a research report on Monday, April 13th. William Blair restated an “outperform” rating on shares of Ocular Therapeutix in a research report on Monday, March 2nd. Royal Bank Of Canada reiterated an “outperform” rating and issued a $30.00 target price on shares of Ocular Therapeutix in a research report on Wednesday, May 6th. Wall Street Zen lowered shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Ocular Therapeutix in a research report on Tuesday, February 17th. Twelve equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Ocular Therapeutix currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.78.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.